Merck & Company Inc (MRK)

73.89
-0.55(-0.74%)
Pre Market
74.06
+0.17(+0.23%)
- Real-time Data
  • Volume:
    15,284,159
  • Bid/Ask:
    73.95/74.10
  • Day's Range:
    73.30 - 74.78

MRK Overview

Prev. Close
74.44
Day's Range
73.3-74.78
Revenue
47.7B
Open
74.38
52 wk Range
68.38-91.4
EPS
2.53
Volume
15,284,159
Market Cap
186.64B
Dividend (Yield)
2.76
(3.71%)
Average Vol. (3m)
16,378,037
P/E Ratio
29.19
Beta
0.5
1-Year Change
-5.3%
Shares Outstanding
2,525,943,936
Next Earnings Date
Feb 03, 2022
What is your sentiment on Merck & Company Inc?
or
Market is currently closed. Voting is open during market hours.

Merck & Company Inc Company Profile

Employees
73500

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals, Inc. to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellNeutral
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellNeutral
  • The US Food and Drug Administration has accepted a Priority Review of the pneumococcal 15-valent conjugate vaccine VAXNEUVANCE™ in children aged 17 years and younger. Merck has a lot of different stuff they are bringing to market
    0
    • 🚀🚀🚀🚀🚀🚀🚀
      0
      • still in red ofcourse but now u have to buy it tp 76$ friday/monday it gets hit. without a headline
        1
        • Biden administration aims to obtain 13M COVID antiviral pills, equitable distributionThere are so many reasons to buy this stock, I'm glad I did.
          0
          • The federal government has agreed to buy 3.1M courses of Merck's antiviral molnupiravir worth ~$2.2B. The government has also agreed to purchase 10M doses of Pfizer's (PFE -2.0%) Paxlovid
            0
        • The German health minister Jens Spahn has just signed the contract with Merck & Co. Inc. about the first shipment of anti-covid-drug Lagevrio. The first shipment will be delivered in December 2021. Source: Handelsblatt
          0
          • Powell says inflation would stay high for a while. That makes money more expensive as base interests and market interests follow the inflation. Not to mention the effects of covid. That makes highly indebted big tech more exposed and less profitable. An obvious choice would be for investors to buy value stocks like MRK and energy, FMCG etc. companies. But no, they buy even more big tech thus blowing the tech bubble even bigger. I guess the tech bubble must explode and than we will see fair pricings again.
            0
            • very good news right ??
              0
            • source ??? cant find anywhere
              0
            • of course you can. FED meeting yesterday or the day before
              0
          • and it ends oh man this is why i traded defensive stocks they dont gain everyday and take profits and trading in typical 5year ranges to break up or breakdown if u place chart weekly/monthly u realize exactly calls where it goes above channel u enter short and opposite its always been lile this verizon aswell, colgate etc, snap on
            0
            • I expected a lot more upwards movement to happen today. If for covid and omikron, the defensive MRK stocks should be a safe haven for investors. Will see if the market stops acting crazy.
              0
              • hope happen as you say
                0
            • France says it has ordered 50,000 doses of Merck's COVID-19 antiviral pill
              0
              • october news
                0
            • U.S. confirms nation’s first case of omicron Covid variant in California
              0
              • Does anyone know that this stock has not risen, the news is very positive though. I was expecting a very nice elevation today, but it havent happened yet.
                0
                • Merck draws mixed views on Street despite backing from FDA panel for COVID-19 pill
                  0
                  • Too close of FDA vote
                    0
                • 🚀🚀🚀🚀🚀🚀🚀
                  3
                  • 77.4 is end channel .
                    5
                    • you are right you are one sided and only a opinion nobody ask or agrees with.
                      0
                    • well looks like im the only one who was right then
                      2
                    • investing.com/equities/merck---co-commentary?comment=30619410
                      0
                  • bought
                    0
                    • Merck’s Covid Treatment Pill Wins Blessing of F.D.A. Panel
                      0
                      • MRK continues its 12-year dividend growth track record with the recent 6% dividend bump to $0.69
                        0
                        • already +6% in Europe (premarket)
                          0
                          • it was strange to watch the +6% premarket fall back to <1% before US market open and than back.
                            0
                        • The stock price should be exceed 90 in very few days…
                          0
                          • The drug, molnupiravir, could provide a much-needed weapon against the virus as colder weather pushes case counts higher and U.S. officials brace for the arrival of the new omicron variant.
                            0
                            • ı wanna ask a question there iş a news about dividend. it is mention about $0.69. Does that mean we're going to get $0.69 per share?
                              0
                              • Yes
                                0
                              • Amr Taherthank you
                                0
                            • Approve Approve Approve. Hopefully stock price reflect it soon!!
                              0
                              • FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questionshttps://www.cnbc.com/2021/11/30/fda-advisory-panel-narrowly-endorses-mercks-oral-covid-treatment-pill-despite-reduced-efficacy.html?__source=androidappshare
                                0
                                • Any news of the FDA approval of molnupiravir yet?
                                  0
                                  • Approval 🚀🚀🚀🚀🚀🚀hopefullyyyy
                                    0
                                  • Still debating yet #ApproveMerck
                                    0
                                • it is also said to be effective against all variants
                                  0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.